Blood Brain Barrier Platform And Rare Disease Pipeline Will Shape Long Term Neurology Potential

Catalysts

About Denali Therapeutics

Denali Therapeutics develops biologic medicines designed to cross the blood brain barrier for rare genetic and common neurodegenerative diseases.

What are the underlying business or industry changes driving this perspective?

• Approval and early uptake of AVLAYAH create a commercial foothold in Hunter syndrome, with US$3.6 million in first full quarter net product revenue that can scale as more of the roughly 375 eligible U.S. pediatric patients and additional new births transition to therapy, which is likely to affect revenue growth and operating leverage.
• The enzyme transport vehicle franchise targets multiple lysosomal storage disorders where biologics are already an accepted treatment class. Denali Therapeutics expects each program to represent several hundred million dollars or more in potential annual market opportunity, which can influence long term revenue diversification and earnings resilience.
• Growing recognition of blood brain barrier transport as a key enabler for neurology biologics, supported by AVLAYAH as the first FDA approved biologic designed to cross the blood brain barrier, may attract broader physician and payer interest in the platform and support pricing power and net margins as additional products reach the market.
• Advancement of DNL921 and DNL628 into Alzheimer’s disease trials fits with the expanding use of biomarkers and genetics in central nervous system drug development. If future data support clinical use in large patient populations this could have a meaningful effect on future revenue scale and overall earnings profile.
• A cash position of more than US$1.1b and internal manufacturing capacity in Salt Lake City provide funding and cost of goods efficiency for multiple parallel programs, which can support sustained R&D investment while helping stabilize operating expenses and, over time, net margins.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Denali Therapeutics's revenue will grow by 371.7% annually over the next 3 years.
• Analysts are not forecasting that Denali Therapeutics will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Denali Therapeutics's profit margin will increase from -14191.2% to the average US Biotechs industry of 16.9% in 3 years.
• If Denali Therapeutics's profit margin were to converge on the industry average, you could expect earnings to reach $63.9 million (and earnings per share of $0.33) by about August 2029, up from -$511.5 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 134.7x on those 2029 earnings, up from -7.8x today. This future PE is greater than the current PE for the US Biotechs industry at 17.3x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.41%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• AVLAYAH is launching into a small and well defined Hunter syndrome population of roughly 375 currently eligible U.S. pediatric patients and about 30 new births each year. If the initial pool of highly engaged families proves to be a one time bolus rather than a sustainable source of new prescriptions, Denali Therapeutics could see slower than expected AVLAYAH uptake after the early years, which would constrain revenue growth and limit operating leverage from the current cost base.
• Competition in Hunter syndrome and related lysosomal storage disorders, including potential gene therapies and other enzyme replacement products such as JCR Pharma’s IZCARGO and resubmitted rival therapies, could limit Denali Therapeutics’ share of what it describes as a multi billion dollar ERT market. This would reduce the revenue contribution and pricing power of the enzyme transport vehicle franchise and weigh on future net margins.
• Denali Therapeutics is investing heavily in Alzheimer’s disease programs DNL921 and DNL628 with initial clinical data not expected until 2027. Any delay, inconclusive biomarker results, or safety issues in these trials could undercut the long term rationale for the blood brain barrier transport platform in common neurodegenerative diseases, resulting in lower than expected earnings potential relative to the company’s current portfolio ambitions.
• The company is supporting a broad pipeline and commercial build out with more than US$1.1b in cash and reported quarterly research and development expenses of US$97 million and selling, general, and administrative expenses of US$36.3 million. If AVLAYAH and future products do not scale as anticipated, sustained high operating expenses could lead to ongoing losses and pressure future earnings and cash balances.
• Denali Therapeutics depends on favorable payer decisions and complex reimbursement processes for rare pediatric disorders where many patients are on Medicaid. If coverage expansion slows, prior authorization hurdles increase, or pricing for high cost biologics faces tighter scrutiny over time, this could impede AVLAYAH treatment starts as well as future ETV launches and compress both revenue and net margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $35.44 for Denali Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $42.0, and the most bearish reporting a price target of just $27.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $378.3 million, earnings will come to $63.9 million, and it would be trading on a PE ratio of 134.7x, assuming you use a discount rate of 7.4%.
• Given the current share price of $24.95, the analyst price target of $35.44 is 29.6% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.